Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Strategic Challenges | Delayed partnership expectations and the speculative nature of oncolytic virus research pose risks, balanced against the potential for breakthrough cancer treatments |
Financial Outlook | Analysts set a $6.00 price target for Oncolytics Biotech, representing significant upside potential from its current trading price of $1.40 |
Regulatory Tailwinds | FDA support for progression-free survival as a primary endpoint could accelerate pelareorep's path to market, streamlining the approval process |
Pelareorep Progress | Oncolytics Biotech's lead candidate, pelareorep, shows promise in cancer treatment, with crucial BRACELET-1 trial results expected in late 2024 |
Metrics to compare | ONC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −3.1x | −0.5x | |
PEG Ratio | 2.10 | 0.00 | 0.00 | |
Price / Book | 11.4x | −0.3x | 2.6x | |
Price / LTM Sales | - | 2.1x | 2.9x | |
Upside (Analyst Target) | - | 122.5% | 57.2% | |
Fair Value Upside | Unlock | −27.7% | 8.9% | Unlock |